

Summary of 3rd Quarter Financial Results for year ended March 31, 2013 (Japan GAAP) (Unaudited)

February 1, 2013

Company name:	Mitsubishi Tanabe Pharma Corporation
Stock exchange listings (Section):	Tokyo, Osaka (First Sections)
Securities code number:	4508
URL:	http://www.mt-pharma.co.jp/
Representative:	Name: Michihiro Tsuchiya Title: President and Representative Director
For further information, please contact:	Name: Yoshihisa Sasou Title: General Manager, Corporate Communications Department Telephone: (06) 6205-5211

Planned date of filing of quarterly securities report: February 8, 2013
 Planned date of start of dividend payments: –
 Provision of supplementary explanatory materials for quarterly results: Yes
 Quarterly results presentation: Yes (for institutional investors and investment analysts)

Notes: Amounts less than ¥ 1 million have been rounded.
 Percentage changes in the list show change in comparison with the previous 3rd quarter.

1. Results for 3rd Quarter (April 1, 2012 to December 31, 2012)

(1) Consolidated Business Results

	Net sales		Operating income		Ordinary income	
	Yen million	% change	Yen million	% change	Yen million	% change
3rd Quarter of Fiscal 2012	322,570	2.2	58,860	(1.8)	60,136	(0.4)
3rd Quarter of Fiscal 2011	315,747	(1.2)	59,936	(13.0)	60,392	(13.0)

	Net income		Net income per share	Net income per share (diluted)
	Yen million	% change	Yen	Yen
3rd Quarter of Fiscal 2012	35,249	(1.7)	62.83	-
3rd Quarter of Fiscal 2011	35,853	(8.7)	63.90	-

(Note) Comprehensive Income ¥36,507 million, 9.5% (¥33,347 million, (7.3)% in 3rd Quarter of fiscal 2011)

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Yen million	Yen million	%
As of December 31, 2012	845,649	733,889	86.3
As of March 31, 2012	819,925	721,485	87.3

(Note) Shareholders' equity ¥729,740 million (¥715,745 million in fiscal 2011)

2. Dividends

(Record date)	Dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year-end	For the year
	Yen	Yen	Yen	Yen	Yen
Fiscal 2011	-	15.00	-	20.00	35.00
Fiscal 2012	-	20.00	-	-	-
Fiscal 2012(projected)	-	-	-	20.00	40.00

(Note) Revision to recently announced dividend forecast: No

3. Forecasts for Fiscal 2012 (April 1, 2012 to March 31, 2013)

	Net sales		Operating income		Ordinary income	
	Yen million	% change	Yen million	% change	Yen million	% change
Full year	425,000	4.4	70,000	1.4	71,000	3.3

	Net income		Net income per share
	Yen million	% change	Yen
Full year	40,500	3.8	72.19

(Note) Revision to recently announced consolidated results forecast: No

※ Notes

- (1) Significant change involving subsidiaries during the period: No
(Change in designated subsidiaries accompanying changes in the scope of consolidation)
- (2) Application of special accounting methods in the preparation of quarterly financial statements: No
- (3) Changes in accounting policies, changes in accounting estimates, and restatements
1. Change accompanying revision of accounting standards: No
 2. Other changes: Yes
 3. Change in accounting estimates: Yes
 4. Restatements: No

(Note)

Changes fall under Article 10(5) of the Ordinance on Terminology, Forms and Preparation Methods of Quarterly Consolidated Financial Statements. For details, please refer to “(1) Changes in accounting policies, changes in accounting estimates, and restatements” under “2. Items Concerning Summary Data (The notes)” on page 5.

(4) Number of shares issued (common stock)

1. Number of shares issued at the end of the period (including treasury stock)

3rd Quarter of fiscal 2012	561,417,916 shares	Fiscal 2011	561,417,916 shares
----------------------------	--------------------	-------------	--------------------

2. Number of shares of treasury stock at the end of the period

3rd Quarter of fiscal 2012	424,294 shares	Fiscal 2011	423,532 shares
----------------------------	----------------	-------------	----------------

3. Average number of shares of during the period (cumulative third quarter)

3rd Quarter of fiscal 2012	560,994,210 shares	3rd Quarter of fiscal 2011	561,064,357 shares
----------------------------	--------------------	----------------------------	--------------------

*Note regarding implementation of quarterly review procedures

At the time when this summary of 3rd quarter financial results was released, the review procedures were in progress for the quarterly financial statements in accordance with the Financial Instruments and Exchange Act.

*Explanation regarding the appropriate use of results forecasts and other matters of special note

(Note about forward-looking information)

In these materials, forecasts of results and other statements about the future are forward-looking statements based on a number of assumptions and beliefs in light of the information available to management as of the date of release of the materials and are subject to risks and uncertainties. Accordingly, the Company cannot make promises to achieve such forecasts. Actual financial results may differ materially from these forecasts depending on a number of important factors.

For matters related to results forecasts, please see page 4.

(Methods of obtaining the supplementary materials and the content of the results presentation)

- Supplementary materials are included from page 12 of this document in section "4. Supplementary information."
- The Company plans to hold a results presentation (conference call) for institutional investors and securities analysts on February 1, 2013 (Friday).

The Company plans to make available on its website the content of the presentation (sound) and the presentation materials immediately after the presentation is held.

Contents of supplement

- 1. Qualitative Information for 3rd Quarter of FY2012 1
 - (1) Qualitative information about consolidated results of operations 1
 - (2) Qualitative information about consolidated financial position 3
 - (3) Qualitative information about consolidated results forecasts 4
- 2. Items Concerning Summary Data (The notes) 5
 - (1) Changes in accounting policies, changes in accounting estimates, and restatements 5
- 3. Consolidated Financial Statements 6
 - (1) Consolidated Balance Sheets 6
 - (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income 8
 - Consolidated Statements of Income 8
 - Consolidated Statements of Comprehensive Income 9
 - (3) Consolidated Statements of Cash Flows 10
 - (4) Note regarding going concern assumption 11
 - (5) Note regarding substantial change in shareholders' equity 11
- 4. Supplementary information 12
 - (1) Consolidated Financial Indicators for 3rd Quarter of FY2012 12
 - (2) State of New Product Development 17

1. [Qualitative Information for 3rd Quarter of FY 2012]

(1) Qualitative information about consolidated results of operations

Consolidated operating results in the third quarter of the fiscal year ended March 31, 2013 (April 1, 2012 to December 31, 2012) were as follows.

(millions of yen)

	3 rd quarter of FY 2011	3 rd quarter of FY 2012	Increase/ Decrease	% change
Net Sales	315,747	322,570	6,823	2.2
Cost of sales	119,325	126,732	7,407	6.2
Cost of sales ratio	37.8%	39.3%		
Gross profit	196,422	195,838	(584)	(0.3)
SG&A expenses	136,486	136,978	492	0.4
Operating Income	59,936	58,860	(1,076)	(1.8)
Non-operating income/loss	456	1,276	820	
Ordinary Income	60,392	60,136	(256)	(0.4)
Extraordinary income/loss	(3,345)	(4,148)	(803)	
Net Income	35,853	35,249	(604)	(1.7)

【Net sales】

Net sales increased 2.2%, or ¥6.8 billion, year-on-year, to ¥322.5 billion.

(millions of yen)

	3 rd quarter of FY 2011	3 rd quarter of FY 2012	Increase/ Decrease	% change
Pharmaceuticals	308,336	318,917	10,581	3.4
Domestic ethical drugs	278,584	278,572	(12)	(0.0)
Overseas ethical drugs	13,857	15,211	1,354	9.8
OTC products	4,359	4,278	(81)	(1.9)
Others in Pharmaceuticals	11,536	20,856	9,320	80.8
Others	7,411	3,653	(3,758)	(50.7)

In the pharmaceuticals segment, net sales were ¥318.9 billion, up 3.4%, or ¥10.5 billion, year-on-year.

- Although there were the NHI drug price revisions implemented in April 2012 and the growing impact of generics, in domestic sales of ethical drugs, sales were expanded by Remicade, an anti-TNF α monoclonal antibody. In addition, Tenelia, for the treatment of type2 diabetes mellitus, and other new drugs which were launched between the previous fiscal year and the current fiscal year made contributions. As a result, the domestic sales of ethical drugs remained the same level as the previous third quarter at ¥278.5 billion.

- Overseas sales of ethical drugs increased 9.8%, year-on-year, to ¥15.2 billion, and sales of OTC products decreased 1.9%, year-on-year, to ¥4.2 billion.
- Sales of others in pharmaceuticals increased 80.8%, year-on-year, to ¥20.8 billion due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis. In the past financial reportings, royalty revenue from Gilenya had been reported one quarter later after it accrued. Since this revenue got to be material and have big impact on the financial result, the accounting process was adjusted to report the forecasted revenue for the quarter on accrual basis from this quarter. As a result, net sales in the current third quarter included the Gilenya royalty revenue from October to December 2012.

In others, sales were down 50.7%, or ¥3.7 billion, year-on-year, due to the transfer of fine chemical operations in July, 2012.

【Operating income】

Operating income decreased 1.8%, or ¥1.0 billion, year-on-year, to ¥58.8 billion.

- Although net sales increased ¥6.8 billion, year-on-year, gross profit decreased ¥0.5 billion, year-on-year, to ¥195.8 billion due to the influence of NHI drug price revisions and other factors. The cost of sales ratio worsened by 1.5 percentage points.
- SG&A expenses increased ¥0.4 billion, year-on-year, to ¥136.9 billion, due to the increase in sales expenses with the amortization of distribution rights for new products launched in the previous fiscal year. R&D expenses were ¥51.2 billion, accounting for 15.9% of net sales.

【Ordinary income and net income】

Ordinary income was down 0.4%, or ¥0.2 billion, year-on-year, to ¥60.1 billion, and net income was down 1.7%, or ¥0.6 billion, year-on-year, to ¥35.2 billion.

- Loss on business integration of the plasma fractionation operations of ¥2.2 billion was recorded as extraordinary loss.
- The Relief Law was revised, so that the time limit for the benefit claim was extended for another five-year period from January, 2013. Accordingly a provision of reserve for HCV litigation of ¥2.0 billion was recorded as extraordinary loss.
- Consequently, extraordinary losses were ¥5.3 billion, including loss on impairment of fixed assets and other items. In the previous fiscal year, the Company recorded extraordinary losses of ¥3.3 billion, such as loss on impairment of fixed assets.

The Relief Law stands for "The Special Relief Law Concerning the Payment of Benefits to Relieve the Patients of Hepatitis C Infected through Specified Fibrinogen Preparations and Specified Blood-Coagulation Factor IX Preparations Contaminated by Hepatitis C Virus."

【Comprehensive income】

Net income before minority interests was ¥35.3 billion, due to other comprehensive income of ¥1.2 billion, and comprehensive income of ¥36.5 billion. Comprehensive income attributable to shareholders of the Company was ¥36.4 billion.

(2) Qualitative information about consolidated financial position

【Balance sheets】

(millions of yen)

	End of FY 2011 (As of March 31, 2012)	End of 3 rd quarter of FY 2012 (As of December 31, 2012)	Increase/ Decrease
Current assets	419,651	451,345	31,694
Fixed assets	400,274	394,304	(5,970)
Total assets	819,925	845,649	25,724
Liabilities	98,440	111,760	13,320
Net assets	721,485	733,889	12,404
Total liabilities and net assets	819,925	845,649	25,724

Total assets at the end of the third quarter were ¥845.6 billion, an increase of ¥25.7 billion from the end of the previous fiscal year. Major factors causing changes in the balance sheet in comparison with the previous year-end were as follows.

- Notes and accounts receivable-trade and deposits increased. Consequently, total current assets were up ¥31.6 billion, to ¥451.3 billion.
- Property, plant and equipment decreased by the depreciation. Consequently, total fixed assets were down ¥5.9 billion from the previous fiscal year-end, to ¥394.3 billion.
- Notes and accounts payable-trade increased. Consequently, total liabilities were up ¥13.3 billion, to ¥111.7 billion.
- Total net assets were up by ¥12.4 billion, to ¥733.8 billion. Net income was ¥35.2 billion, and dividends paid totaled ¥22.4 billion. As a result, retained earnings increased ¥12.8 billion. The equity ratio was 86.3%, compared with 87.3% a year earlier.

【Cash flows】

(millions of yen)

		3 rd quarter of FY 2011	3 rd quarter of FY 2012	Increase/ Decrease
	Operating activities	14,745	41,270	26,525
	Investing activities	(57,685)	(9,406)	48,279
	Financing activities	(17,289)	(23,677)	(6,388)
	Change in cash and cash equivalents	(60,743)	8,190	68,933
	At beginning of year	97,880	54,344	(43,536)
	At end of year	37,137	62,534	25,397

Net increase in cash and cash equivalents was ¥8.1 billion, and the balance of cash and cash equivalents at the end of the period under review was ¥62.5 billion.

- Net cash provided by operating activities was ¥41.2 billion. Cash inflows included income before income taxes and minority interests of ¥55.9 billion, and increase in notes and accounts payable-trade of ¥13.7 billion, while cash outflows included increase in notes and accounts receivable-trade of ¥19.7 billion and income taxes paid of ¥17.6 billion.
- Net cash used in investing activities was ¥9.4 billion, due to increase in deposits for investment purposes.
- Net cash used in financing activities was ¥23.6 billion, due in part to dividends paid.

(3) Qualitative information about consolidated results forecasts

There are no revisions to the full-year results forecasts for the fiscal year ending March 31, 2013, which were announced on October 29, 2012.

Consolidated results forecasts for the current fiscal year (released on October 29, 2012)

(millions of yen)

	Results for FY 2011	Forecasts for FY 2012	Increase/ Decrease	% change
Net sales	407,156	425,000	17,844	4.4
Operating income	69,043	70,000	957	1.4
Ordinary income	68,759	71,000	2,241	3.3
Net income	39,014	40,500	1,486	3.8

2. [Items Concerning Summary Data (The notes)]

(1) Changes in accounting policies, changes in accounting estimates and restatements

(Changes in depreciation method of property, plant and equipment)

Previously, the Company and the domestic consolidated subsidiaries calculated depreciation of property, plant and equipment - except for buildings acquired on or after April 1, 1998, including equipment attached to the buildings - primarily by the declining-balance method. However, from the first quarter of the current consolidated fiscal year, the Company and domestic consolidated subsidiaries have changed it to the straight-line method.

The Company expects new drugs launched in the previous consolidated fiscal year to make a contribution to sales in the current consolidated fiscal year. In addition, the Company plans to launch multiple drugs of new types in the next fiscal year and thereafter. In the Group's operating environment, there are demands for the strengthening of safety measures after products are manufactured and sold. In this environment, the Group's policy is to rapidly collect and accumulate safety and efficacy data for the purpose of promoting the appropriate usage of these new drugs, and to conduct sales while formulating further safety measures as needed. Accordingly, the trend toward more-gradual growth in revenues/profits will steadily strengthen.

In addition, in October 2011, the Group formulated "Medium-Term Management Plan 11-15 ~New Value Creation" of which fiscal 2015 will be the final year, and announced aggressive upfront investment to strengthen its foundation and expand its business toward sustained growth. The Group undertakes full-scale implementation of this investment plan from the current consolidated fiscal year.

At this turning point, through deliberations regarding the reevaluation of the depreciation method, the Group confirmed that its product lines are expected to secure stable revenues/profits over the long term; that its property, plant and equipment are, in general, in stable operation; and that the upfront investment will contribute to further stable operation through consolidation and strengthening of production equipments.

Accordingly, in the judgment of the Group, the allocation of expenses through uniform depreciation over the useful life of the property, plant and equipment will enable the actual usage conditions of the Group's property, plant and equipment to be reflected appropriately. Therefore, the Group reevaluated the previous depreciation method and decided to use the straight-line method from the first quarter of the current consolidated fiscal year.

In comparison with the previous method, in the cumulative third quarter of the current fiscal year, this change had the effect of increasing gross profit, by ¥837 million, operating income by ¥1,815 million, and ordinary income and income before income taxes and minority interests by ¥1,845 million, respectively.

3. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(millions of yen)

Year Accounts	As of March 31, 2012	As of December 31, 2012
	Amount	Amount
Assets		
Current assets		
Cash and time deposits	15,466	20,969
Notes and accounts receivable, trade	127,207	146,953
Marketable securities	46,345	45,117
Merchandise and finished goods	64,259	60,416
Work in process	897	849
Raw materials and supplies	21,034	23,297
Deposits	130,791	141,369
Deferred income taxes	9,343	5,898
Other	4,350	6,523
Less allowance for doubtful receivables	(41)	(46)
Total current assets	419,651	451,345
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	37,522	33,418
Machinery, equipment and vehicles, net	15,348	12,053
Tools, furniture and fixtures, net	4,040	4,431
Land	46,359	44,409
Leased equipment, net	66	63
Construction in progress	594	1,458
Total property, plant and equipment	103,929	95,832
Intangible fixed assets		
Goodwill	105,549	102,132
Other	3,806	4,015
Total intangible fixed assets	109,355	106,147
Investments and other assets		
Investment in securities	116,596	112,531
Deferred income taxes	7,898	10,208
Prepaid pension expenses	42,101	38,318
Other	20,397	31,270
Less allowance for doubtful receivables	(2)	(2)
Total investments and other assets	186,990	192,325
Total fixed assets	400,274	394,304
Total assets	819,925	845,649

(millions of yen)

Year Accounts	As of	As of
	March 31, 2012	December 31, 2012
	Amount	Amount
Liabilities		
Current liabilities		
Notes and accounts payable, trade	28,878	42,660
Short-term debt	2,170	949
Accounts payable, other	15,723	16,873
Income taxes payable	6,726	9,654
Reserve for employees' bonuses	11,121	5,300
Other reserve	212	471
Other	4,754	7,327
Total current liabilities	69,584	83,234
Long-term liabilities		
Deferred income taxes	9,338	9,191
Accrued retirement benefits for employees	10,584	9,630
Reserve for health management allowances for HIV compensation	1,461	1,461
Reserve for health management allowances for SMON compensation	3,622	3,261
Reserve for HCV litigation	2,520	3,704
Other	1,331	1,279
Total long-term liabilities	28,856	28,526
Total liabilities	98,440	111,760
Net assets		
Shareholders' equity		
Common stock	50,000	50,000
Capital surplus	451,186	451,186
Retained earnings	224,168	236,978
Treasury stock, at cost	(486)	(486)
Total shareholders' equity	724,868	737,678
Accumulated other comprehensive loss		
Unrealized holding gains (losses) on securities	(82)	243
Deferred (losses) gains on hedges	93	1,010
Translation adjustments	(9,134)	(9,191)
Total accumulated other comprehensive loss	(9,123)	(7,938)
Minority interests	5,740	4,149
Total net assets	721,485	733,889
Total liabilities and net assets	819,925	845,649

**(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)**

(millions of yen)

Year Accounts	April 01, 2011- December 31, 2011	April 01, 2012- December 31, 2012
	Amount	Amount
Net sales	315,747	322,570
Cost of sales	119,325	126,732
Gross profit	196,422	195,838
Selling, general and administrative expenses		
Advertising expenses	2,742	3,021
Sales promotion expenses	8,135	7,458
Salaries and allowances	25,989	25,077
Provision for bonuses	3,044	2,934
Retirement benefit expenses	3,896	4,105
Depreciation and amortization	1,221	927
Research and development expenses	51,625	51,233
Amortization of goodwill	7,597	7,689
Other	32,237	34,534
Total selling, general and administrative expenses	136,486	136,978
Operating income	59,936	58,860
Non-operating income		
Interest income	1,146	1,215
Dividend income	776	779
Equity in earning of affiliates	633	661
Other	750	1,535
Total non-operating income	3,305	4,190
Non-operating expenses		
Interest expense	13	34
Foreign exchange loss	745	1,071
Donations	349	427
Other	1,742	1,382
Total non-operating expenses	2,849	2,914
Ordinary income	60,392	60,136
Extraordinary income		
Gain on sales of property, plant and equipment	-	646
Gain on transfer of business	-	354
Gain on sales of investment in securities	-	201
Total extraordinary income	-	1,201
Extraordinary loss		
Loss on business integration	-	2,219
Provision of reserve for HCV litigation	-	2,020
Loss on sales of investment in securities	-	385
Loss on impairment of fixed assets	2,923	348
Loss on valuation of investment in securities	103	123
Other	319	254
Total extraordinary losses	3,345	5,349
Income before income taxes and minority interests	57,047	55,988
Income taxes-current	16,725	20,435
Income taxes-deferred	4,270	253
Total income taxes	20,995	20,688
Net income before minority interests	36,052	35,300
Minority interests	199	51
Net income	35,853	35,249

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

Year Accounts	April 01, 2011- December 31, 2011	April 01, 2012- December 31, 2012
	Amount	Amount
Net income before minority interests	36,052	35,300
Other comprehensive income (loss)		
Unrealized holding gains (losses) on securities	(1,112)	329
Deferred (losses) gains on hedges	(276)	917
Translation adjustments	(1,313)	(41)
Other comprehensive loss of equity method companies attributable to the Company	(4)	2
Total other comprehensive income (loss)	(2,705)	1,207
Comprehensive income	33,347	36,507
Comprehensive income (loss) attributable to:		
Shareholders of the Company	33,417	36,434
Minority interests	(70)	73

(3) Consolidated Statements of Cash Flows

(millions of yen)

Year Accounts	April 01, 2011- December 31, 2011	April 01, 2012- December 31, 2012
Cash flows from operating activities:		
Income before income taxes and minority interests	57,047	55,988
Depreciation and amortization	9,022	6,303
Loss on impairment of fixed assets	2,923	348
Amortization of goodwill	7,597	7,689
Increase (decrease) in accrued retirement benefits for employees	(931)	(950)
Decrease (increase) in prepaid pension expenses	(1,247)	3,783
Increase (decrease) in reserve for HCV litigation	(1,959)	1,184
Interest and dividend income	(1,922)	(1,994)
Loss (gain) on sale of property, plant and equipment	122	(508)
Loss (gain) on transfer of business	-	(354)
Loss (gain) on sale of investment in securities	-	184
Loss (gain) on valuation of investment in securities	103	123
Equity in (earnings) losses of affiliates	(633)	(661)
Loss on business integration	-	2,219
Decrease (increase) in notes and accounts receivable, trade	(17,965)	(19,735)
Decrease (increase) in inventories	(5,757)	(10,030)
Increase (decrease) in notes and accounts payable, trade	10,062	13,793
Increase (decrease) in accounts payable, other	(2,213)	1,154
Other, net	(13,206)	(1,776)
Subtotal	41,043	56,760
Interest and dividends received	1,982	2,180
Interest paid	(5)	(27)
Income taxes paid	(28,275)	(17,643)
Net cash provided by (used in) operating activities	14,745	41,270
Cash flows from investing activities:		
Purchase of marketable securities	(34,648)	(42,250)
Proceeds from sales and redemption of marketable securities	69,542	49,720
Increase in time deposits	(1,939)	(45)
Decrease in time deposits	11,172	978
Increase in deposits	(96,692)	(10,534)
Increase in long-term deposits	(406)	-
Decrease in long-term deposits	-	1,875
Purchase of property, plant and equipment	(7,282)	(6,167)
Proceeds from sales of property, plant and equipment	77	2,700
Purchase of intangible fixed assets	(692)	(1,413)
Purchase of investment in securities	(1,252)	(4,250)
Purchase of investment in subsidiaries	-	(6,015)
Proceeds from sales and redemption of investment in securities	4,449	4,591
Proceeds from transfer of business	-	1,384
Other, net	(14)	20
Net cash provided by (used in) investing activities	(57,685)	(9,406)
Cash flows from financing activities:		
Increase (decrease) in short-term debt, net	(952)	(1,214)
Cash dividends paid	(16,270)	(22,439)
Other, net	(67)	(24)
Net cash provided by (used in) financing activities	(17,289)	(23,677)
Effect of exchange rate change on cash and cash equivalents	(514)	3
Net increase (decrease) in cash and cash equivalents	(60,743)	8,190
Cash and cash equivalents at beginning of the year	97,880	54,344
Cash and cash equivalents at end of the period	37,137	62,534

(4) Note regarding going concern assumption

Not applicable.

(5) Note regarding substantial change in shareholders' equity

Not applicable.

4. Supplementary Information

(1) Consolidated Financial Indications for 3rd Quarter of FY2012

i. PL (cumulative 3rd quarter)

[Billion yen]

	Cumulative Q3/FY2012		Cumulative Q3/FY2011		Year-on-year		Comparison to forecasts		Notes [year-on-year comparison]
		Composition %		Composition %	Increase (decrease)	Change %	Forecasts for FY2012*1	Achieved %	
Net sales	322.5	100.0	315.7	100.0	6.8	2.2	425.0	75.9	Average exchange rate Cumulative Q3 FY2012: 1US \$ = ¥ 79.23 Cumulative Q3 FY2011: 1US \$ = ¥ 80.21
[Domestic]	[290.6]	[90.1]	[295.1]	[93.5]	[(4.5)]	[(1.6)]	[384.0]	[75.7]	
[Overseas]	[31.9]	[9.9]	[20.5]	[6.5]	[11.4]	[55.5]	[41.0]	[77.9]	
Pharmaceuticals	318.9	98.9	308.3	97.7	10.5	3.4	420.5	75.8	Ethical drugs overseas sales +1.3 Contracted manufacturing products (1.4) Licensing fee, etc. +10.8 See page 14, Sales of Main Products
[Domestic]	[288.4]	[89.4]	[289.7]	[91.8]	[(1.3)]	[(0.5)]	[382.0]	[75.5]	
[Overseas]	[30.5]	[9.5]	[18.5]	[5.9]	[11.9]	[64.5]	[38.5]	[79.2]	
Others	3.6	1.1	7.4	2.3	(3.7)	(50.7)	4.5	81.2	Decrease according to transfer of fine chemical operations
[Domestic]	[2.2]	[0.7]	[5.4]	[1.7]	[(3.1)]	[(59.2)]	[2.0]	[110.4]	
[Overseas]	[1.4]	[0.4]	[2.0]	[0.6]	[(0.5)]	[(27.9)]	[2.5]	[57.8]	
Cost of sales	126.7	39.3	119.3	37.8	7.4	6.2	167.0	75.9	
Gross operation profit	195.8	60.7	196.4	62.2	(0.5)	(0.3)	258.0	75.9	
SG&A expenses	136.9	42.5	136.4	43.2	0.4	0.4	188.0	72.9	
R&D expenses	51.2	15.9	51.6	16.4	(0.3)	(0.8)	70.0	73.2	
Non-R&D expenses	85.7	26.6	84.8	26.9	0.8	1.0	118.0	72.7	
Labor costs	38.4	11.9	38.8	12.3	(0.4)	(1.1)	51.5	74.6	
Amortization of goodwill*2	7.6	2.4	7.5	2.4	0.0	1.2	10.2	75.4	
Others	39.6	12.3	38.4	12.2	1.2	3.1	56.3	70.4	Increase in amortization of distribution rights, etc.
Operating income	58.8	18.2	59.9	19.0	(1.0)	(1.8)	70.0	84.1	
Non-operating income	4.1		3.3		0.8				
Interest income	1.2		1.1		0.0				
Dividend income	0.7		0.7		0.0				
Equity in earnings of income	0.6		0.6		0.0				
Others	1.5		0.7		0.7				
Non-operating expenses	2.9		2.8		0.0				
Currency exchange loss	1.0		0.7		0.3				
Donations	0.4		0.3		0.0				
Others	1.4		1.7		(0.3)				
Ordinary income	60.1	18.6	60.3	19.1	(0.2)	(0.4)	71.0	84.7	
Extraordinary income	1.2		-		1.2				
Gains on sale of property, plant and equipment	0.6		-		0.6				
Gains on transfer of business	0.3		-		0.3				Gains on transfer of fine chemical operations
Gains on sale of investment in securities	0.2		-		0.2				
Extraordinary loss	5.3		3.3		2.0				
Loss on business integration	2.2		-		2.2				Loss according to integration of plasma fractionation operations
Provision of reserve for HCV litigation	2.0		-		2.0				
Loss on sale of investment in securities	0.3		-		0.3				Choseido Pharmaceutical
Loss on impairment of fixed assets	0.3		2.9		(2.5)				FY2012: Nabari No.2 training center, etc. FY2011: Sanban-cho office, Tokyo
Loss on valuation of investment in securities	0.1		0.1		0.0				
Others	0.2		0.3		0.0				
Net income	35.2	10.9	35.8	11.4	(0.6)	(1.7)	40.5	87.0	
Total labor cost	66.5	20.6	66.5	21.1	0.0	(0.1)	89.0	74.7	

*1: Published forecasts announced on Oct. 29, 2012 in the financial results for 2nd quarter of FY2012

*2: Clear off 150.5 billion yen within 15 years

ii. Sales of Main Products (cumulative 3rd quarter)

[Billion yen]

	Cumulative Q3/FY2012	Year-on-year			Comparison to forecasts	
		Cumulative Q3/FY2011	Increase (decrease)	Change %	Forecasts for FY2012*1	Achieved %
Ethical drugs	314.6	303.9	10.6	3.5	415.0	75.8
Ethical drugs domestic sales	278.5	278.5	0.0	0.0	369.0	75.5
Remicade	56.5	50.9	5.5	10.9	75.0	75.4
Ceredist	14.4	14.0	0.4	3.3	19.0	76.3
Talion	8.9	9.2	(0.2)	(2.7)	15.0	59.8
Maintate	10.9	10.6	0.2	2.7	15.0	72.9
Radicut	10.6	18.7	(8.0)	(43.2)	14.0	76.1
Anplag	10.3	12.1	(1.8)	(15.4)	13.5	76.4
Urso	10.4	11.3	(0.9)	(8.5)	13.5	77.2
Kremezin	9.4	9.0	0.4	4.7	12.5	76.0
Venoglobulin IH	8.7	8.3	0.4	5.2	11.5	76.0
Depas	8.1	8.5	(0.4)	(4.9)	10.5	77.4
Telavic	4.4	0.1	4.3	-	8.5	52.9
Herbesser	6.0	6.8	(0.8)	(12.2)	7.5	80.5
Tanatril	5.6	6.6	(1.0)	(15.1)	7.0	80.8
Lexapro	3.0	0.7	2.2	-	5.5	55.9
Simponi	3.7	0.4	3.3	-	7.0	54.0
Liple	4.0	4.8	(0.8)	(17.6)	5.0	80.3
Neuart	3.5	4.2	(0.6)	(15.7)	4.5	79.8
BIKEN Products [Vaccine]	23.9	24.5	(0.5)	(2.2)	29.5	81.3
Mearubik	6.1	7.4	(1.2)	(17.4)	8.0	77.0
Influenza	8.3	8.7	(0.4)	(4.9)	8.5	98.1
JEBIK V	4.1	6.1	(2.0)	(33.1)	6.0	68.9
Tanabe Seiyaku Hanbai Products *2	14.6	13.4	1.2	9.0	19.0	76.9
Ethical drugs overseas sales	15.2	13.8	1.3	9.8	23.5	64.7
Herbesser	3.4	3.6	(0.1)	(4.9)	6.0	57.3
Argatroban (Novastan)	1.8	2.4	(0.5)	(22.5)	2.5	75.4
Tanatril	1.2	1.3	0.0	(4.0)	2.0	64.5
Vaccine	1.6	1.2	0.3	29.2	2.0	81.7
Contracted manufacturing products *3	5.0	6.5	(1.4)	(22.7)	7.0	72.2
Licensing fee, etc.	15.8	5.0	10.8	216.1	15.5	102.0
Royalty from Gilenya	13.9	3.3	10.5	314.0	-	-
OTC products	4.2	4.3	0.0	(1.9)	5.5	77.8
Total pharmaceuticals	318.9	308.3	10.5	3.4	420.5	75.8

*1: Published forecasts announced on Oct. 29, 2012, in the financial results for 2nd quarter of FY2012

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC

*3: Active pharmaceutical ingredients, and others ordered by other companies.

iii. Sales of Main Products (3rd quarter)

[Billion yen]

	Q3/FY2012 Oct. to Dec.	Year-on-year			Comparison to forecasts	
		Q3/FY2011 Oct. to Dec.	Increase (decrease)	Change %	Forecasts for 2nd half of FY2012	Achieved %
Ethical drugs	116.7	111.4	5.2	4.7	217.0	53.8
Ethical drugs domestic sales	101.9	102.8	(0.9)	(0.9)	192.3	53.0
Remicade	19.8	18.9	0.9	4.8	38.2	51.8
Ceredist	4.9	5.1	(0.1)	(2.8)	9.4	52.4
Talion	3.6	3.9	(0.2)	(5.4)	9.7	38.0
Maintate	3.9	4.0	0.0	(2.2)	8.0	49.3
Radicut	3.6	5.9	(2.2)	(38.2)	7.0	52.3
Anplag	3.5	4.4	(0.9)	(21.8)	6.6	52.4
Urso	3.6	4.1	(0.5)	(12.5)	6.7	54.4
Kremezin	3.4	2.8	0.6	21.1	6.4	53.8
Venoglobulin IH	3.2	3.2	0.0	(2.1)	5.9	53.8
Depas	2.8	3.1	(0.2)	(8.7)	5.2	54.5
Telavic	1.0	0.1	0.8	474.9	5.0	20.5
Herbesser	2.1	2.4	(0.3)	(14.7)	3.5	59.2
Tanatril	1.9	2.3	(0.4)	(17.8)	3.3	59.3
Lexapro	1.4	0.3	1.0	300.3	3.8	36.7
Simponi	1.5	0.3	1.1	325.1	4.7	32.6
Liple	1.4	1.7	(0.3)	(19.2)	2.3	58.9
Neuart	1.3	1.6	(0.3)	(20.1)	2.2	59.9
BIKEN Products [Vaccine]	11.3	9.4	1.9	20.8	16.8	67.4
Mearubik	0.7	1.1	(0.4)	(37.0)	2.5	28.7
Influenza	6.8	6.4	0.3	5.8	6.9	97.6
JEBIK V	0.5	1.2	(0.7)	(56.3)	2.4	23.1
Tanabe Seiyaku Hanbai Products *1	5.5	5.2	0.3	6.5	9.9	55.9
Ethical drugs overseas sales	5.0	4.7	0.3	7.2	13.3	37.8
Herbesser	1.1	1.3	(0.1)	(13.9)	3.6	30.8
Argatroban (Novastan)	0.4	0.7	(0.2)	(37.2)	1.1	44.5
Tanatril	0.4	0.4	0.0	(10.2)	1.1	37.4
Vaccine	0.6	0.3	0.2	87.1	0.9	63.0
Contracted manufacturing products *2	1.2	1.7	(0.4)	(27.2)	3.2	39.6
Licensing fee, etc.	8.4	2.0	6.3	301.7	8.1	103.8
Royalty from Gilenya	7.9	1.6	6.2	379.5	-	-
OTC products	1.4	1.4	0.0	(0.3)	2.6	54.6
Total pharmaceuticals	118.1	112.9	5.2	4.7	219.7	53.8

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC

*2: Active pharmaceutical ingredients, and others ordered by other companies.

iv. Quarterly Trend (PL)

[Billion yen]

	FY2011					FY2012			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2011 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Forecast for FY2012
Net sales	102.2	98.1	115.3	91.4	407.1	104.3	99.4	118.7	425.0
	25.1%	24.1%	28.3%	22.5%	100.0%	24.6%	23.4%	27.9%	100.0%
Domestic	95.7	91.4	108.0	83.6	378.8	95.6	89.7	105.2	384.0
	25.3%	24.1%	28.5%	22.1%	100.0%	24.9%	23.4%	27.4%	100.0%
Overseas	6.5	6.6	7.3	7.7	28.3	8.7	9.6	13.5	41.0
	23.1%	23.5%	25.9%	27.5%	100.0%	21.4%	23.5%	33.0%	100.0%
Pharmaceuticals	99.7	95.6	112.9	89.2	397.5	101.9	98.8	118.1	420.5
	25.1%	24.1%	28.4%	22.4%	100.0%	24.2%	23.5%	28.1%	100.0%
Domestic	93.7	89.8	106.2	82.0	371.8	93.7	89.6	105.0	382.0
	25.2%	24.2%	28.6%	22.1%	100.0%	24.5%	23.5%	27.5%	100.0%
Overseas	6.0	5.8	6.6	7.1	25.6	8.2	9.1	13.1	38.5
	23.4%	22.7%	26.0%	27.8%	100.0%	21.4%	23.8%	34.1%	100.0%
Others	2.5	2.4	2.4	2.1	9.5	2.4	0.6	0.5	4.5
	26.1%	25.4%	25.7%	22.8%	100.0%	54.8%	13.9%	12.4%	100.0%
Domestic	1.9	1.6	1.8	1.5	6.9	1.8	0.1	0.1	2.0
	28.3%	23.4%	26.0%	22.4%	100.0%	95.0%	6.8%	8.7%	100.0%
Overseas	0.5	0.8	0.6	0.6	2.6	0.5	0.4	0.3	2.5
	20.3%	30.9%	24.9%	23.9%	100.0%	22.7%	19.6%	15.5%	100.0%
Cost of sales	37.3	37.0	44.8	32.9	152.2	40.6	38.6	47.4	167.0
Sales Cost Ratio	36.5%	37.8%	38.9%	36.1%	37.4%	38.9%	38.8%	40.0%	39.3%
Gross operating profit	64.8	61.0	70.5	58.4	254.8	63.7	60.8	71.2	258.0
	25.5%	23.9%	27.7%	22.9%	100.0%	24.7%	23.6%	27.6%	100.0%
SG&A expenses	42.1	47.7	46.6	49.3	185.8	44.9	47.4	44.6	188.0
	22.7%	25.7%	25.1%	26.6%	100.0%	23.9%	25.2%	23.8%	100.0%
R&D expenses	15.7	17.8	18.0	18.6	70.2	16.9	17.3	16.9	70.0
	22.4%	25.4%	25.7%	26.5%	100.0%	24.2%	24.7%	24.3%	100.0%
Non-R&D expenses	26.4	29.8	28.5	30.7	115.5	27.9	30.0	27.6	118.0
	22.9%	25.9%	24.7%	26.6%	100.0%	23.7%	25.5%	23.4%	100.0%
Labor costs	12.6	13.3	12.9	13.1	51.9	12.9	13.0	12.4	51.5
	24.3%	25.6%	24.9%	25.2%	100.0%	25.1%	25.3%	24.2%	100.0%
Amortization of goodwill	2.5	2.5	2.5	2.5	10.1	2.5	2.5	2.6	10.2
	25.0%	25.0%	25.0%	25.0%	100.0%	24.8%	24.8%	25.7%	100.0%
Others	11.2	14.0	13.0	15.0	53.4	12.5	14.5	12.5	56.3
	21.1%	26.3%	24.5%	28.2%	100.0%	22.3%	25.8%	22.3%	100.0%
Operating income	22.7	13.3	23.8	9.1	69.0	18.8	13.4	26.6	70.0
	32.9%	19.3%	34.6%	13.2%	100.0%	26.9%	19.2%	38.0%	100.0%
Ordinary income	22.9	13.3	24.0	8.3	68.7	19.6	13.4	27.0	71.0
	33.4%	19.5%	34.9%	12.2%	100.0%	27.7%	19.0%	38.1%	100.0%
Net income	11.4	8.5	15.8	3.1	39.0	10.8	8.6	15.7	40.5
	29.3%	21.9%	40.7%	8.1%	100.0%	26.7%	21.4%	38.9%	100.0%

The each figure (excluding Cost of sales) in the lower displays the progress rate.

v. Quaterly Trend (Sales of Main Products)

[Billion yen]

	FY2011					FY2012			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2010 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Forecast for FY2012
Ethical drugs	98.3 25.1%	94.2 24.0%	111.4 28.4%	88.1 22.5%	392.1 100.0%	100.5 24.2%	97.3 23.5%	116.7 28.1%	415.0 100.0%
Ethical drugs domestic sales	89.7 25.3%	85.9 24.2%	102.8 28.9%	76.8 21.6%	355.4 100.0%	90.5 24.5%	86.1 23.3%	101.9 27.6%	369.0 100.0%
Remicade	15.8 23.9%	16.2 24.5%	18.9 28.5%	15.3 23.1%	66.3 100.0%	17.9 23.9%	18.7 25.0%	19.8 26.4%	75.0 100.0%
Ceredist	4.6 25.9%	4.2 23.7%	5.1 28.4%	3.9 22.0%	18.0 100.0%	5.0 26.3%	4.5 23.8%	4.9 26.1%	19.0 100.0%
Talion	3.0 22.9%	2.2 16.9%	3.9 29.3%	4.1 30.9%	13.3 100.0%	3.0 20.3%	2.2 14.8%	3.6 24.6%	15.0 100.0%
Maintate	3.4 24.9%	3.1 23.3%	4.0 29.6%	3.0 22.3%	13.6 100.0%	3.6 24.2%	3.3 22.2%	3.9 26.4%	15.0 100.0%
Radicut	6.7 29.9%	6.0 26.9%	5.9 26.4%	3.7 16.7%	22.4 100.0%	3.7 26.5%	3.2 23.3%	3.6 26.3%	14.0 100.0%
Anplag	4.0 26.8%	3.6 23.7%	4.4 29.4%	3.0 20.1%	15.2 100.0%	3.6 27.1%	3.1 23.3%	3.5 25.9%	13.5 100.0%
Urso	3.7 26.2%	3.4 23.6%	4.1 28.9%	3.0 21.3%	14.4 100.0%	3.4 25.9%	3.2 24.2%	3.6 27.1%	13.5 100.0%
Kremezin	2.8 24.4%	3.3 28.6%	2.8 24.8%	2.5 22.1%	11.6 100.0%	3.1 25.1%	2.8 23.0%	3.4 28.0%	12.5 100.0%
Venoglobulin IH	2.4 23.3%	2.5 23.8%	3.2 30.6%	2.3 22.2%	10.6 100.0%	2.8 24.9%	2.6 23.3%	3.2 27.8%	11.5 100.0%
Depas	2.8 25.5%	2.6 24.0%	3.1 28.3%	2.4 22.2%	10.9 100.0%	2.7 26.3%	2.5 24.1%	2.8 27.0%	10.5 100.0%
Telavic	-	-	0.1 12.0%	1.3 88.0%	1.4 100.0%	2.1 25.3%	1.3 15.5%	1.0 12.1%	8.5 100.0%
Herbesser	2.3 27.0%	2.0 23.6%	2.4 28.8%	1.7 20.6%	8.6 100.0%	2.1 28.1%	1.8 24.0%	2.1 28.3%	7.5 100.0%
Tanatril	2.2 27.3%	2.0 24.0%	2.3 28.6%	1.6 20.1%	8.3 100.0%	1.9 28.1%	1.7 24.7%	1.9 28.0%	7.0 100.0%
Lexapro	-	0.4 34.9%	0.3 28.0%	0.4 37.1%	1.2 100.0%	0.7 13.7%	0.9 16.6%	1.4 25.6%	5.5 100.0%
Simponi	-	0.0 5.0%	0.3 38.4%	0.5 56.6%	0.9 100.0%	1.0 14.9%	1.1 16.9%	1.5 22.2%	7.0 100.0%
Liple	1.6 26.6%	1.4 23.9%	1.7 28.1%	1.3 21.4%	6.2 100.0%	1.4 28.0%	1.2 24.2%	1.4 28.1%	5.0 100.0%
Neuart	1.2 23.9%	1.2 23.9%	1.6 31.6%	1.1 20.6%	5.3 100.0%	1.1 25.9%	1.0 23.8%	1.3 30.1%	4.5 100.0%
BIKEN products [Vaccine]	7.0 24.4%	8.0 28.0%	9.4 32.7%	4.2 14.8%	28.8 100.0%	6.1 20.7%	6.5 22.0%	11.3 38.6%	29.5 100.0%
Mearubik	4.1 43.6%	2.1 22.2%	1.1 12.3%	2.0 21.9%	9.5 100.0%	3.3 42.1%	2.0 25.7%	0.7 9.3%	8.0 100.0%
Influenza	0.0 (0.1%)	2.3 26.0%	6.4 71.2%	0.2 3.0%	9.0 100.0%	0.0 (0.5%)	1.5 18.5%	6.8 80.0%	8.5 100.0%
JEBIK V	2.0 29.3%	2.8 39.3%	1.2 18.0%	0.9 13.4%	7.1 100.0%	1.7 29.8%	1.7 29.8%	0.5 9.4%	6.0 100.0%
Tanabe Seiyaku Hanbai products *1	4.3 24.9%	3.8 22.0%	5.2 29.8%	4.0 23.3%	17.4 100.0%	4.8 25.5%	4.2 22.3%	5.5 29.2%	19.0 100.0%
Ethical drugs overseas sales	4.6 25.3%	4.4 24.2%	4.7 25.5%	4.6 24.9%	18.4 100.0%	4.5 19.4%	5.6 23.9%	5.0 21.5%	23.5 100.0%
Herbesser	1.1 24.6%	1.0 22.5%	1.3 27.1%	1.2 25.7%	4.8 100.0%	1.1 19.1%	1.1 19.3%	1.1 19.0%	6.0 100.0%
Argatroban (Novastan)	0.9 32.3%	0.6 21.1%	0.7 25.6%	0.6 21.0%	3.0 100.0%	0.7 28.6%	0.6 27.0%	0.4 19.8%	2.5 100.0%
Tanatril	0.3 22.9%	0.4 28.2%	0.4 27.7%	0.3 21.3%	1.7 100.0%	0.4 22.5%	0.4 20.8%	0.4 21.2%	2.0 100.0%
Vaccine	0.4 29.8%	0.4 29.1%	0.3 21.0%	0.3 20.0%	1.5 100.0%	0.2 13.7%	0.7 36.9%	0.6 31.2%	2.0 100.0%
Contracted manufacturing products *2	2.4 28.3%	2.3 26.9%	1.7 20.2%	2.1 24.6%	8.6 100.0%	1.7 24.6%	2.0 29.3%	1.2 18.2%	7.0 100.0%
Licensing fee, etc.	1.4 15.0%	1.4 15.2%	2.0 21.9%	4.5 47.9%	9.5 100.0%	3.7 24.4%	3.5 23.2%	8.4 54.4%	15.5 100.0%
OTC products	1.4 26.4%	1.4 27.0%	1.4 27.3%	1.0 19.3%	5.4 100.0%	1.3 24.7%	1.4 26.4%	1.4 26.7%	5.5 100.0%
Total pharmaceuticals	99.7 25.1%	95.6 24.1%	112.9 28.4%	89.2 22.4%	397.5 100.0%	101.9 24.2%	98.8 23.5%	118.1 28.1%	420.5 100.0%

The each figure in the lower displays the progress rate.

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2: Active pharmaceutical ingredients and others ordered by other companies.

(2) State of New Product Development (As of Feb. 1, 2013)

1. Pipeline in Japan

New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Phase 3	In-house
MP-214 (Cariprazine)	D3/D2 receptor partial agonist (Schizophrenia)	Phase 2b/3	Hungary: Gedeon-Richter
MP-435	C5a receptor antagonist (Rheumatoid arthritis)	Phase 2	In-house
MT-4666	$\alpha 7nACh$ receptor agonist (Alzheimer's disease)	Phase 2	US: EnVivo
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Phase 1	In-house
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Phase 1	In-house

Additional Indications

Product name (Generic name)	Category (Indications)	Stage	Origin
Omeprazon (Omeprazole)	Proton pump inhibitor (<i>Helicobacter pylori</i> eradication by concomitant therapy for <i>Helicobacter pylori</i> gastritis)	sNDA filed	UK:AstraZeneca
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	sNDA filed	Switzerland: Merck Serono
Grtpa (Alteplase[recombinant])	Thrombolytic agent (Acute ischemic cerebrovascular disease [up to 4.5 hours after the onset of symptoms])	sNDA filed	US:Genentech
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Phase 3	Japan: Ube Industries
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [genotype2])	Phase 3	US:Vertex
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	Phase 3	In-house
Remicade (Infliximab [recombinant])	Anti- human TNF α monoclonal antibody (Refractory Kawasaki disease*)	Phase 3	US:Janssen Biotech
	(Behcet's disease with special lesions*)	Phase 3	
	(Pediatric Crohn's disease)	Phase 3	
	(Pediatric ulcerative colitis)	Phase 3	
	(Psoriasis: increased dose)	Phase 3	
Cholebine (Colestimide[JAN])	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1	

* Orphan drug designated

2. Pipelines Overseas

New Molecular Entities

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Taiwan	Filed	US:Vertex
MT-9938 (Nalfurafine)	κ -opioid receptor agonist (Refractory pruritus)	US	Phase 2	Japan:Toray
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house
		US	Phase 1	
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Europe	Phase 1	In-house
MP-157	Angiotensin Type 2 receptor agonist (Hypertention)	Europe	Phase 1	In-house
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Europe	Phase 1	In-house
MT-7716	NOP receptor agonist (Alcohol-use disorder)	US	Phase 1	In-house

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Europe	MAA filed (Mar. 2012)	US: Vivus
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	US	NDA filed (May 2012)	US: Janssen Pharmaceuticals
		Europe	MAA filed (Jun. 2012)	
	(Obesity)	US, Europe	Phase 2	
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	Phase 3	Korea: Handok Pharmaceuticals
T-0047 (Finategrast)	Cell adhesion inhibitor [$\alpha4\beta7/\alpha4\beta1$ inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK: GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US: MediciNova
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
MCC-847	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma (Sidem)
TT-138	$\beta3$ receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US: MediciNova
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism)	Japan	Phase 1	Japan: Kyowa Hakko Kirin
Wf-516	SSRI / 5HT1A receptor antagonists (Depression)	Europe	Phase 1	US: SONKEI Pharmaceuticals

4. Changes Since Previous Announcement on Oct. 29, 2012

In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of October 29, 2012	As of February 1, 2013
MCI-196/BindRen (Colestilan[INN])	Non-absorbed phosphate binder (Hyperphosphatemia)	Europe	MAA filed (Aug. 2011)	Approved (January, 2013)
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Taiwan	None	Filed (January, 2013)
MT-9938 (Nalfurafine)	κ -opioid receptor agonist (Refractory pruritus)	US	None	Phase 2
MT-4666	$\alpha 7nACh$ receptor agonist (Alzheimer's disease)	Japan	Phase 1	Phase 2

Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of October 29, 2012	As of February 1, 2013
MCC-847	Leukotriene D4 receptor antagonist (Asthma)	Korea	None	Phase 2
MT-4580	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	Japan	None	Phase 1
Wf-516	SSRI / 5HT1A receptor antagonists (Depression)	Europe	None	Phase 1